Haisco Pharmaceutical Group Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in China. It offers pharmaceutical products in the areas of anesthesia and analgesic, endocrine system, enteral parenteral nutrition, cardiovascular, psychiatric, tumor-related, digestive liver, and other diseases. Haisco Pharmaceutical Group Co., Ltd. has licensing and research collaboration with Eli Lilly and Company to develop medicines across multiple therapeutic areas. The company was formerly known as Xizang Haisco Pharmaceutical Group Co., Ltd. and changed its name to Haisco Pharmaceutical Group Co., Ltd. in March 2016. Haisco Pharmaceutical Group Co., Ltd. was founded in 2000 and is based in Shannan, China.
Research context
Haisco Pharmaceutical Group Co., Ltd appears in PyInvesting’s Shenzhen Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 7 months ago
Haisco Pharmaceutical Group Co., Ltd is currently in a long term downtrend where the price is trading 8.1% below its 200 day moving average.
From a valuation standpoint, the stock is 9.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.7.
Haisco Pharmaceutical Group Co., Ltd's total revenue rose by 0.4% to $954M since the same quarter in the previous year.
Its net income has increased by 111.3% to $234M since the same quarter in the previous year.
Finally, its free cash flow fell by 119.2% to $-21M since the same quarter in the previous year.
Based on the above factors, Haisco Pharmaceutical Group Co., Ltd gets an overall score of 3/5.